The oxytocin antagonist atosiban <i>versus</i> the β‐agonist terbutaline in the treatment of preterm labor

,

doi:10.1034/j.1600-0412.2001.d01-456.x

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2005

2014

Publication Types

Select...

Other3

Article1

Book1

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 46 publications

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Oxytocin receptor antagonists for inhibiting preterm labour

Papatsonis

Flenady

Cole

et al. 2005

Cochrane Database of Systematic Reviews

154

View full text Add to dashboard Cite

Analysis 1.3. Comparison 1 Atosiban versus placebo, Outcome 3 Neonatal death (up to 28 days).. .. .. .. Analysis 1.4. Comparison 1 Atosiban versus placebo, Outcome 4 Infant death (up to 12 months).. .. .. .. Analysis 1.5. Comparison 1 Atosiban versus placebo, Outcome 5 Preterm birth less than 28 weeks' gestation.. .. Analysis 1.6. Comparison 1 Atosiban versus placebo, Outcome 6 Preterm birth less than 37 weeks' gestation.. .. Analysis 1.7. Comparison 1 Atosiban versus placebo, Outcome 7 Birth within 48 hours of initiation of treatment. .

show abstract

Oxytocin receptor antagonists for inhibiting preterm labour

Papatsonis

Flenady

Cole

et al. 2005

Cochrane Database of Systematic Reviews

154

View full text Add to dashboard Cite

show abstract

Oxytocin receptor antagonists for inhibiting preterm labour

Flenady

Reinebrant

Liley

et al. 2014

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

This review did not demonstrate superiority of ORA (largely atosiban) as a tocolytic agent compared with placebo, betamimetics or CCB (largely nifedipine) in terms of pregnancy prolongation or neonatal outcomes, although ORA was associated with less maternal adverse effects than treatment with the CCB or betamimetics. The finding of an increase in infant deaths and more births before completion of 28 weeks of gestation in one placebo-controlled study warrants caution. However, the number of women enrolled at very low gestations was small. Due to limitations of small numbers studied and methodological quality, further well-designed randomised controlled trials are needed. Further comparisons of ORA versus CCB (which has a better side-effect profile than betamimetics) are needed. Consideration of further placebo-controlled studies seems warranted. Future studies of tocolytic agents should measure all important short- and long-term outcomes for women and infants, and costs.

show abstract

Atosiban

2007

Neonatal Formulary

View full text Add to dashboard Cite

The oxytocin antagonist atosiban versus the β‐agonist terbutaline in the treatment of preterm labor

Abstract: The efficacy of atosiban in the inhibition of preterm labor was shown to be comparable to terbutaline. Atosiban had a superior safety profile compared with terbutaline in terms of maternal and fetal adverse events, and comparable infant outcomes.

Cited by 46 publications

References 45 publications

Oxytocin receptor antagonists for inhibiting preterm labour

Oxytocin receptor antagonists for inhibiting preterm labour

Oxytocin receptor antagonists for inhibiting preterm labour

Atosiban

Contact Info

Product

Resources

About